Lower DNA methylation levels in CpG island shores of CR1, CLU, and PICALM in the blood of Japanese Alzheimer’s disease patients

Background: The APOE ɛ4 allele is the strongest known genetic risk factor for sporadic Alzheimer’s disease (AD). The neighboring TOMM40 gene has also been implicated in AD due to its close proximity to APOE. Objective: Here we tested whether methylation of the TOMM40-APOE locus may influence ApoE protein levels and AD pathology. Methods: DNA methylation levels across the TOMM40-APOE locus and ApoE levels were measured in superior frontal gyrus tissues of 62 human brains genotyped for APOE and scored for AD neuropathology. Results: Methylation levels within the TOMM40 CpG island in the promoter or APOE CpG island in Exon 4 did not differ between APOE ɛ4 carriers versus non-carriers. However, APOE ɛ4 carriers had significantly higher methylation the APOE promoter compared with non-carriers. Although DNA methylation at TOMM40, APOE promoter region, or APOE did not differ between AD pathological groups, there was a negative association between TOMM40 methylation and CERAD scores. ApoE protein concentrations did not significantly different between APOE ɛ4 carriers and non-carriers, or between AD pathological groups. Finally, there was no correlation between ApoE protein concentrations and DNA methylation levels. Conclusion: APOE gene methylation may not be affected by genotype, relate to AD pathology or ApoE protein levels in the superior frontal gyrus, though, DNA methylation at the ApoE promoter differed between genotype. DNA methylation at TOMM40 associated with amyloid-β plaques and longitudinal fluid intelligence. In sum, these results suggest a complicated regulation of the TOMM40-APOE locus in the brain in controlling ApoE protein levels and AD neuropathology.

Download Full-text

Lower DNA methylation levels in CpG island shores of CR1, CLU, and PICALM genes in the blood of Alzheimer’s disease patients

10.1101/2020.03.14.20035683 ◽

2020 ◽

Author(s):

Risa Mitsumori ◽

Kazuya Sakaguchi ◽

Shumpei Niida ◽

Nobuyoshi Shimoda

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Dna Methylation ◽

Sanger Sequencing ◽

Late Onset ◽

Cpg Island ◽

Diagnostic Value ◽

Replication Analysis ◽

The Relationship ◽

Six Genes

AbstractThe aim of the present study was to (1) investigate the relationship between late onset AD and DNA methylation levels in the top six Alzheimer’s disease (AD)-related genes in blood and (2) examine its applicability to the diagnosis of AD. We examined methylation differences at CpG island shores in the top six genes using Sanger sequencing, and one of two groups of 48 AD patients and 48 elderly controls was used for a test or replication analysis. We found that methylation levels in three out of the six genes, CR1, CLU, and PICALM, were lower in AD subjects. The combination of CLU methylation levels and the APOE genotype classified AD patients with AUC=0.84 and 0.80 in the test and replication analyses, respectively. Our results implicate methylation differences at the CpG island shores of AD-related genes in the onset of AD and suggest their diagnostic value.

Download Full-text

GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer’s Disease Patients

Current Alzheimer Research ◽

10.2174/1567205014666170203153325 ◽

2017 ◽

Vol 14 (7) ◽

Cited By ~ 13

Author(s):

Vincenzina Nicolia ◽

Viviana Ciraci ◽

Rosaria A. Cavallaro ◽

Isidre Ferrer ◽

Sigfrido Scarpa ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Dna Methylation

Download Full-text

DNA methylation signature of human hippocampus in Alzheimer’s disease is linked to neurogenesis

Clinical Epigenetics ◽

10.1186/s13148-019-0672-7 ◽

2019 ◽

Vol 11 (1) ◽

Cited By ~ 11

Author(s):

Miren Altuna ◽

Amaya Urdánoz-Casado ◽

Javier Sánchez-Ruiz de Gordoa ◽

María V. Zelaya ◽

Alberto Labarga ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Dna Methylation ◽

Human Hippocampus

Download Full-text

DNA methylation alterations in Alzheimer’s disease

Environmental Epigenetics ◽

10.1093/eep/dvx008 ◽

2017 ◽

Vol 3 (2) ◽

Cited By ~ 19

Author(s):

Amy S. Yokoyama ◽

John C. Rutledge ◽

Valentina Medici

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Dna Methylation

Download Full-text

Prediction of Alzheimer's disease based on deep neural network by integrating gene expression and DNA methylation dataset

Expert Systems with Applications ◽

10.1016/j.eswa.2019.112873 ◽

2020 ◽

Vol 140 ◽

pp. 112873 ◽

Cited By ~ 5

Author(s):

Chihyun Park ◽

Jihwan Ha ◽

Sanghyun Park

Keyword(s):

Neural Network ◽

Gene Expression ◽

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Dna Methylation ◽

Deep Neural Network

Download Full-text

Epigenome-wide meta-analysis of DNA methylation differences in prefrontal cortex implicates the immune processes in Alzheimer’s disease

Nature Communications ◽

10.1038/s41467-020-19791-w ◽

2020 ◽

Vol 11 (1) ◽

Author(s):

Lanyu Zhang ◽

Tiago C. Silva ◽

Juan I. Young ◽

Lissette Gomez ◽

Michael A. Schmidt ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Dna Methylation ◽

Prefrontal Cortex ◽

Biomarker Discovery ◽

Meta Analysis ◽

Enrichment Analysis ◽

Braak Stage ◽

Polycomb Repressive Complex 2 ◽

Differentially Methylated Genes

AbstractDNA methylation differences in Alzheimer’s disease (AD) have been reported. Here, we conducted a meta-analysis of more than 1000 prefrontal cortex brain samples to prioritize the most consistent methylation differences in multiple cohorts. Using a uniform analysis pipeline, we identified 3751 CpGs and 119 differentially methylated regions (DMRs) significantly associated with Braak stage. Our analysis identified differentially methylated genes such as MAMSTR, AGAP2, and AZU1. The most significant DMR identified is located on the MAMSTR gene, which encodes a cofactor that stimulates MEF2C. Notably, MEF2C cooperates with another transcription factor, PU.1, a central hub in the AD gene network. Our enrichment analysis highlighted the potential roles of the immune system and polycomb repressive complex 2 in pathological AD. These results may help facilitate future mechanistic and biomarker discovery studies in AD.

Download Full-text

Longitudinal data in peripheral blood confirm that PM20D1 is a quantitative trait locus (QTL) for Alzheimer’s disease and implicate its dynamic role in disease progression

Clinical Epigenetics ◽

10.1186/s13148-020-00984-5 ◽

2020 ◽

Vol 12 (1) ◽

Author(s):

Qi Wang ◽

Yinghua Chen ◽

Benjamin Readhead ◽

Kewei Chen ◽

Yi Su ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Dna Methylation ◽

Longitudinal Data ◽

Disease Progression ◽

Peripheral Blood ◽

Early Stage ◽

Underlying Mechanism ◽

Methylation Data ◽

Brain Tissues

Abstract Background While Alzheimer’s disease (AD) remains one of the most challenging diseases to tackle, genome-wide genetic/epigenetic studies reveal many disease-associated risk loci, which sheds new light onto disease heritability, provides novel insights to understand its underlying mechanism and potentially offers easily measurable biomarkers for early diagnosis and intervention. Methods We analyzed whole-genome DNA methylation data collected from peripheral blood in a cohort (n = 649) from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and compared the DNA methylation level at baseline among participants diagnosed with AD (n = 87), mild cognitive impairment (MCI, n = 175) and normal controls (n = 162), to identify differentially methylated regions (DMRs). We also leveraged up to 4 years of longitudinal DNA methylation data, sampled at approximately 1 year intervals to model alterations in methylation levels at DMRs to delineate methylation changes associated with aging and disease progression, by linear mixed-effects (LME) modeling for the unchanged diagnosis groups (AD, MCI and control, respectively) and U-shape testing for those with changed diagnosis (converters). Results When compared with controls, patients with MCI consistently displayed promoter hypomethylation at methylation QTL (mQTL) gene locus PM20D1. This promoter hypomethylation was even more prominent in patients with mild to moderate AD. This is in stark contrast with previously reported hypermethylation in hippocampal and frontal cortex brain tissues in patients with advanced-stage AD at this locus. From longitudinal data, we show that initial promoter hypomethylation of PM20D1 during MCI and early stage AD is reversed to eventual promoter hypermethylation in late stage AD, which helps to complete a fuller picture of methylation dynamics. We also confirm this observation in an independent cohort from the Religious Orders Study and Memory and Aging Project (ROSMAP) Study using DNA methylation and gene expression data from brain tissues as neuropathological staging (Braak score) advances. Conclusions Our results confirm that PM20D1 is an mQTL in AD and demonstrate that it plays a dynamic role at different stages of the disease. Further in-depth study is thus warranted to fully decipher its role in the evolution of AD and potentially explore its utility as a blood-based biomarker for AD.

Download Full-text